Compare Novartis AG (NVS) vs Open Text Corporation (OTEX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Open Text Corporation — how do they compare? Novartis AG trades at $154.71 (market cap $298.18B), while Open Text Corporation trades at $24.05 (market cap $5.98B). The key difference: Novartis AG is far larger — about 49.9× Open Text Corporation's market cap, and Open Text Corporation pays the higher dividend (4.53%). Which is the better fit depends on your goals.
| NVS | OTEX | |
|---|---|---|
Market Cap | $298.18B | $5.98B |
Sector | Health | Technology |
52-Week High | $168.62 | $39.69 |
52-Week Low | $119.31 | $20.01 |
Enterprise Value | $339.50B | $11.00B |
Dividend Yield | 3.02% | 4.53% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $156.33, up 1.37% on the day, with a bullish technical signal and strong support near $156. The company reported Q2 2026 earnings that beat expectations, driven by robust oncology drug sales, and reaffirmed full-year guidance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%, while valuation ratios like P/E of 23.61 and P/B of 7.15 reflect premium pricing. Recent news highlights institutional buying and CEO confidence in the growth pipeline.
The outlook for NVS is positive, supported by earnings momentum and a diversified drug portfolio, but risks include generic competition for Entresto and pricing pressures. Analyst consensus is mixed with 24% buy ratings, indicating cautious optimism. Investment appeal hinges on execution of new drug launches and offsetting legacy product declines.
Open Text Corporation (OTEX) trades at $24.94, down 2.81% in the last session, with a bullish technical signal from moving averages and strong support at $24. The company reported Q2 2026 EPS of $1.23, beating estimates, and maintains robust profitability with a 73.74% gross margin. Recent news highlights cloud revenue growth and a $105 million AI investment in Europe, signaling strategic expansion.
OTEX presents a value opportunity with a low P/E of 9.58 and a consensus price target of $29.33, implying 17.6% upside. Risks include high long-term debt of $6.34 billion and competitive pressures in software. Analyst sentiment is mixed, with 42% buy ratings, but earnings beats and dividend stability support a constructive outlook for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Open Text Corporation
Open Text Corporation is a global leader in Enterprise Information Management (EIM) software and solutions. The company provides a comprehensive platform that helps organizations manage, secure, and leverage their unstructured digital content, including documents, emails, and media files. OTEX's offerings span content management, business process management, customer experience management, and security, serving large enterprises across various industries worldwide.
Read more on OTEX →
